{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:40:12Z","timestamp":1759045212827,"version":"3.44.0"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Intrahepatic cholangiocarcinoma is a rare disease, yet with rising incidence globally. Most patients are not eligible for potentially curative surgical resection, and many patients with unresectable disease die within 12 months of diagnosis, primarily due to liver failure from the primary tumor. Recent prospective and retrospective studies indicate that local control of the primary tumor can be achieved with hypofractionated radiotherapy in patients with unresectable disease, translating into prolonged survival of these patients. During the time that these encouraging reports for radiotherapy have been published, numerous concurrent studies have also shown that intrahepatic cholangiocarcinoma is a molecularly diverse disease with multiple targetable genetic alterations and a complex tumor microenvironment. These biological insights have translated into new drug approvals for subsets of patients. We review the current knowledge about the biology and targeted treatment of intrahepatic cholangiocarcinoma and describe these developments in the context of modern radiotherapy.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000685","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T11:06:09Z","timestamp":1696503969000},"page":"272-278","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma?"],"prefix":"10.1097","volume":"29","author":[{"given":"Eugene J.","family":"Koay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Belknap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrey","family":"Derasari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Millicent","family":"Roach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan B.","family":"Ludmir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250928","doi-asserted-by":"crossref","first-page":"293","DOI":"10.21037\/jgo.2016.10.01","article-title":"Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications","volume":"8","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"bib2-20250928","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","year":"2017","journal-title":"Gut Liver"},{"key":"bib3-20250928","first-page":"297","article-title":"The immunogenomic landscape of resected intrahepatic cholangiocarcinoma","volume":"75","year":"2021","journal-title":"Hepatology"},{"key":"bib4-20250928","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"bib5-20250928","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","year":"2017","journal-title":"Cell Rep"},{"key":"bib6-20250928","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib7-20250928","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","year":"2012","journal-title":"Nat Genet"},{"key":"bib8-20250928","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41467-022-29164-0","article-title":"Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma","volume":"13","year":"2022","journal-title":"Nat Commun"},{"key":"bib9-20250928","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","year":"2023","journal-title":"Lancet Oncol"},{"key":"bib10-20250928","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","year":"2016","journal-title":"Cancer"},{"key":"bib11-20250928","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib12-20250928","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","year":"2015","journal-title":"J Hematol Oncol"},{"key":"bib13-20250928","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib14-20250928","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","year":"2023","journal-title":"Lancet"},{"key":"bib15-20250928","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","year":"2022","journal-title":"N Engl J Med Evid"},{"key":"bib16-20250928","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"bib17-20250928","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"key":"bib18-20250928","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed advanced biliary tract cancers","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib20-20250928","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jso.27012","article-title":"Patient reported outcomes: financial toxicity is a barrier to clinical trials and personalized therapy in cholangiocarcinoma","volume":"126","year":"2022","journal-title":"J Surg Oncol"},{"key":"bib21-20250928","article-title":"A novel patient-centric longitudinal data registry platform to generate insights into real-world cholangiocarcinoma (CCA) clinical practice","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib22-20250928","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jnci\/djad046","article-title":"Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma","volume":"115","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"bib24-20250928","first-page":"7","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","year":"2019","journal-title":"Liver Int"},{"key":"bib25-20250928","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.3748\/wjg.v19.i46.8595","article-title":"Intraductal papillary neoplasm of the bile duct","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"key":"bib26-20250928","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"bib27-20250928","first-page":"628","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","year":"2020","journal-title":"JCO Glob Oncol"},{"journal-title":"Chin Clin Oncol","article-title":"Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma","year":"2019","key":"bib28-20250928"},{"key":"bib29-20250928","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials","volume":"112","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"bib30-20250928","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib31-20250928","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2022.02.013","article-title":"Prognostic impact of FGFR2\/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study","volume":"166","year":"2022","journal-title":"Eur J Cancer"},{"key":"bib32-20250928","doi-asserted-by":"crossref","first-page":"1137510","DOI":"10.3389\/fonc.2023.1137510","article-title":"Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue","volume":"13","year":"2023","journal-title":"Front Oncol"},{"key":"bib33-20250928","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","year":"2022","journal-title":"Ann Oncol"},{"key":"bib34-20250928","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"key":"bib35-20250928","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","year":"2020","journal-title":"Ann Oncol"},{"key":"bib36-20250928","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"bib37-20250928","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","year":"2023","journal-title":"Lancet Oncol"},{"key":"bib38-20250928","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"bib39-20250928","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.celrep.2017.05.014","article-title":"Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation","volume":"19","year":"2017","journal-title":"Cell Rep"},{"key":"bib40-20250928","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-17-0015","article-title":"Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells","volume":"77","year":"2017","journal-title":"Cancer Res"},{"key":"bib41-20250928","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib42-20250928","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","article-title":"Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib43-20250928","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"bib44-20250928","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"key":"bib45-20250928","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","year":"2021","journal-title":"JAMA Oncol"},{"key":"bib46-20250928","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"key":"bib47-20250928","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"bib48-20250928","article-title":"Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib49-20250928","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","year":"2019","journal-title":"Br J Cancer"},{"key":"bib50-20250928","article-title":"Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German tertiary care hospital","volume":"19","year":"2018","journal-title":"Int J Mol Sci"},{"key":"bib51-20250928","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","year":"2020","journal-title":"Int J Cancer"},{"key":"bib52-20250928","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","year":"2017","journal-title":"Science"},{"key":"bib53-20250928","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib54-20250928","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1002\/cam4.1734","article-title":"Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma","volume":"7","year":"2018","journal-title":"Cancer Med"},{"key":"bib55-20250928","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000530134","article-title":"Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases","volume":"12","year":"2023","journal-title":"Liver Cancer"},{"key":"bib56-20250928","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cncr.30488","article-title":"Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients","volume":"123","year":"2017","journal-title":"Cancer"},{"key":"bib57-20250928","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00261-018-1505-4","article-title":"Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?","volume":"43","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"bib58-20250928","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1148\/radiol.2018181485","article-title":"Intrahepatic mass-forming cholangiocarcinoma: arterial enhancement patterns at MRI and prognosis","volume":"290","year":"2019","journal-title":"Radiology"},{"key":"bib59-20250928","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.29878","article-title":"Solutions that enable ablative radiotherapy for large liver tumors: fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance","volume":"122","year":"2016","journal-title":"Cancer"},{"key":"bib60-20250928","article-title":"Benchmarking outcomes after ablative radiotherapy for molecularly characterized intrahepatic cholangiocarcinoma","volume":"11","year":"2021","journal-title":"J Pers Med"},{"key":"bib61-20250928","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/cncr.34223","article-title":"Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: patterns of care and survival in the United States","volume":"128","year":"2022","journal-title":"Cancer"},{"key":"bib62-20250928","doi-asserted-by":"crossref","first-page":"687904","DOI":"10.3389\/fonc.2021.687904","article-title":"A bibliometric analysis of 8,276 publications during the past 25 years on cholangiocarcinoma by machine learning","volume":"11","year":"2021","journal-title":"Front Oncol"},{"key":"bib63-20250928","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"bib64-20250928","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","year":"2022","journal-title":"Am J Transplant"},{"key":"bib65-20250928","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jnci\/djt001","article-title":"Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials","volume":"105","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"bib66-20250928","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1200\/JCO.2011.41.0076","article-title":"Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib67-20250928","article-title":"Artificial intelligence and machine learning in prostate cancer patient management\u2014current trends and future perspectives","volume":"11","year":"2021","journal-title":"Diagnostics (Basel)"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:00:22Z","timestamp":1759042822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000685","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}